Performance on the Cogstate Brief Battery Is Related to Amyloid Levels and Hippocampal Volume in Very Mild Dementia

AuthorsLim, YY.
Villemagne, VL.
Laws, SM.
Pietrzak, RH.
Ames, D.
Fowler, C.
Rainey-Smith, S.
Synder, PJ.
Bourgeat P.
Martins RN.
Salvado O1.
Rowe, CC.
Mastrs, CL.
Maruff, P.
AIBL Research Group.
TypeJournal Article (Original Research)
JournalJournal of Molecular Neuroscience
PubMed ID27586003
Year of Publication2016
URLhttp://www.ncbi.nlm.nih.gov/pubmed/27586003
DOIhttp://dx.doi.org/10.1007/s12031-016-0822-8
Download 2016_Sep_Rowe.pdf (423.2 KB)
AbstractIn a group of older adults with very mild dementia, we aimed to characterize the nature and magnitude of cognitive decline as measured by the Cogstate Brief Battery, in relation to Aβ levels and hippocampal volume. Participants were characterized according to their status on the Clinical Dementia Rating (CDR) scale. A total of 308 individuals who were CDR 0 and had low cerebral Aβ levels (Aβ-), 32 individuals who were Aβ- and CDR 0.5, and 43 individuals who were Aβ+ and CDR 0.5 were included in this study. Participants completed the CogState brief battery at baseline, and at 18-, 36-, 54- and 72-month follow-up. Linear mixed model analyses indicated that relative to the Aβ- CDR 0 group, the Aβ+ CDR 0.5 group showed increased rates of memory decline and hippocampal volume loss. However, compared to the Aβ- CDR 0 group, the Aβ- CDR 0.5 group showed no changes in cognitive function or hippocampal volume over 72 months. The results of this study confirm that in individuals with very mild dementia, who also have biomarker confirmation of Aβ+, changes in cognitive function manifest primarily as deterioration in memory processing, and this is associated with hippocampal volume loss. Conversely, the absence of any cognitive decline or loss in hippocampal volume in individuals with very mild dementia but who are Aβ- suggests that some other non-AD disease process may underlie any static impairment in cognitive function.

http://www.ibas.org.au/what-we-do/publications/3872854


< More publications



Respiratory Biomarkers in Motor Neurone DiseaseRESPIRATORY BIOMARKERS IN MOTOR NEURONE DISEASE

The inability to breathe is unfortunately the most common cause of death in people living with Motor Neurone Disease (MND). Last year, our clinical research group in Melbourne reported that breathing...

Notch monitoring in sleepNOTCH MONITORING IN SLEEP

Sleep apnea is a condition where breathing is abnormal during sleep. There are two main forms of sleep apnea: obstructive and central. For obstructive sleep apnea, breathing is reduced because the airway...

ResearchFest 2026RESEARCHFEST 2026

ResearchFest 2026 at Austin Health launched new research flagships and honored Professor Mark Howard (Distinguished Scientist) and Professor Eliza Hawkes (Women in Research Award), with insights from Peter Doherty.

Championing Sleep Research!CHAMPIONING SLEEP RESEARCH!

We are announcing exciting updates to our Early and Mid-Career Researcher (EMCR) representation at the Institute for Breathing and Sleep (IBAS). The MSRC extend a warm thank you to Charissa Zaga and welcome Jessica Manousakis!

ANZSRS Life Membership for Danny BrazzaleANZSRS LIFE MEMBERSHIP FOR DANNY BRAZZALE

Danny Brazzale has earned a prestigious ANZSRS Life Membership—held by only 11 people—for his global leadership and dedicated mentorship in respiratory science.

Perth Highlights: TSANZSRS 2026PERTH HIGHLIGHTS: TSANZSRS 2026

A huge congratulations to all our team members who participated in the excellent workshops and meetings at the TSANZSRS Annual Scientific Meeting in Perth in March 2026! Well Done!

Institute for Breathing and Sleep

Level 5, Harold Stokes Building, Austin Health
145 Studley Road
Heidelberg, Victoria, 3084

(03) 9496 5390

Email Us

Donate